Additionally, RAS antagonists, such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) may suppress tumor progression in a variety of human or mouse cancer, including lung cancer and pancreatic cancer (30–32), and losartan is the world’s first non-peptide AT1R antagonist for clinical use. The gene discussed is ACE; the disease is pancreatic neoplasm.